PMID- 20922438
OWN - NLM
STAT- MEDLINE
DCOM- 20110906
LR  - 20221207
IS  - 1435-5604 (Electronic)
IS  - 0914-8779 (Linking)
VI  - 29
IP  - 3
DP  - 2011 May
TI  - The effects of intravenous zoledronic acid in Chinese women with postmenopausal 
      osteoporosis.
PG  - 328-33
LID - 10.1007/s00774-010-0223-y [doi]
AB  - The aim of this study was to assess the efficacy and safety of a once-yearly 
      zoledronic acid treatment for Chinese women with postmenopausal osteoporosis in 
      Taiwan and Hong Kong. This post hoc subpopulation analysis, from the Health 
      Outcome and Reduced Incidence with Zoledronic Acid One Yearly Pivotal Fracture 
      Trial, enrolled 323 Chinese women with osteoporosis who were randomly given 
      either annual infusions of zoledronic acid or placebo for 3 consecutive years. 
      The incidence of fractures and changes in bone mineral density (BMD) were 
      measured; adverse events (AEs) and tolerability were recorded and assessed. The 
      results of this study at 36 months demonstrate that there was a significantly 
      reduced risk of morphometric vertebral fracture and clinical vertebral fracture 
      in subjects treated with zoledronic acid (P < 0.05). In addition, there were 
      significant increases of BMD by 4.9%, 4.3%, and 7.0% in the total hip, femoral 
      neck, and trochanter, respectively, in the zoledronic acid group compared with 
      the placebo group (P < 0.001 for all comparisons). The incidences of AEs were 
      comparable between the two groups. Thus, once-yearly zoledronic acid treatment 
      showed bone protection effects by reducing the risk of vertebral fracture and 
      increasing BMD in Chinese women with postmenopausal osteoporosis.
FAU - Hwang, Jawl-Shan
AU  - Hwang JS
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine, Chang 
      Gung Memorial Hospital, Chang Gung University, Linkou, Kaohsiung, Taiwan, ROC.
FAU - Chin, Lin-Show
AU  - Chin LS
FAU - Chen, Jung-Fu
AU  - Chen JF
FAU - Yang, Tzay-Shing
AU  - Yang TS
FAU - Chen, Po-Quang
AU  - Chen PQ
FAU - Tsai, Keh-Sung
AU  - Tsai KS
FAU - Leung, Ping Chung
AU  - Leung PC
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20101005
PL  - Japan
TA  - J Bone Miner Metab
JT  - Journal of bone and mineral metabolism
JID - 9436705
RN  - 0 (Bone Density Conservation Agents)
RN  - 0 (Diphosphonates)
RN  - 0 (Imidazoles)
RN  - 6XC1PAD3KF (Zoledronic Acid)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Asian People
MH  - Bone Density
MH  - Bone Density Conservation Agents/administration & dosage/adverse 
      effects/therapeutic use
MH  - China/epidemiology
MH  - Demography
MH  - Diphosphonates/administration & dosage/adverse effects/*therapeutic use
MH  - Female
MH  - Femoral Neck Fractures/complications/epidemiology
MH  - Hip Fractures/complications/epidemiology
MH  - Humans
MH  - Imidazoles/administration & dosage/adverse effects/*therapeutic use
MH  - Incidence
MH  - Injections, Intravenous
MH  - Middle Aged
MH  - Osteoporosis, Postmenopausal/complications/*drug therapy
MH  - Zoledronic Acid
EDAT- 2010/10/06 06:00
MHDA- 2011/09/07 06:00
CRDT- 2010/10/06 06:00
PHST- 2010/05/01 00:00 [received]
PHST- 2010/08/25 00:00 [accepted]
PHST- 2010/10/06 06:00 [entrez]
PHST- 2010/10/06 06:00 [pubmed]
PHST- 2011/09/07 06:00 [medline]
AID - 10.1007/s00774-010-0223-y [doi]
PST - ppublish
SO  - J Bone Miner Metab. 2011 May;29(3):328-33. doi: 10.1007/s00774-010-0223-y. Epub 
      2010 Oct 5.